.
MergerLinks Header Logo

Announced

Completed

KIRKBI led a $100m Series B funding round in Kerecis.

Financials

Edit Data
Transaction Value£81m
Consideration TypeCash
Capital Owned-
Capital Bid For16%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private

Minority

Completed

Iceland

Friendly

Private Equity

Pharmaceuticals

Venture Capital

Acquisition

Cross Border

drug discovery

Synopsis

Edit

KIRKBI, a private holding and investment company, led a $100m Series B funding round in Kerecis, a manufacturer of fish skin-based therapeutic products, with participation from Emerson Collective, BRU and LSV. "Kerecis is a highly innovative company that has built a successful business transforming waste material into unique medical products. We are particularly inspired by the company's approach to sustainability, as we are responsible investors and owners. We are excited to support the company’s continued growth and strategic objectives to improve patient outcomes," Niklas Sjöblom, KIRKBI Senior Director, Long-Term Equity.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US